Fundraising FoxeTheRNA Immunotherapies
Niel, BE · 12 known investors
Find your way into eTheRNA Immunotherapies
Sign up to see every warm intro you have to eTheRNA Immunotherapies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the eTheRNA Immunotherapies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Etherna is an RNA-LNP technology company that develops proprietary RNA chemistry and lipid nanoparticle delivery platforms for nucleic acid–based therapeutics, and partners with pharma and biotech organizations from early discovery through clinical development. It also runs its own therapeutic pipeline and operates a cGMP-accredited RNA manufacturing facility in Niel, Belgium.
Investors · 12
How we know: Fund+'s portfolio page · prnewswire.com · Not right? Tell us
How we know: PMV's portfolio page · funding news · prnewswire.com · Not right? Tell us
How we know: funding news · prnewswire.com · Not right? Tell us
How we know: prnewswire.com · Not right? Tell us
How we know: labiotech.eu · Not right? Tell us
Also in the syndicate · 5
Funding
SEC filings, press & company announcements- Undisclosed amountseries B2Aug 2022 · 2 sources
Novalis LifeSciences LLC (lead), EQT Life Sciences, Fund+, Grand Pharma, Omega Fund, PWV
Source ↗ - Undisclosed amountSeries BJun 2020
BNP Paribas Fortis Private Equity, Boehringer Ingelheim Venture Fund, Fund+, Grand Decade, LSP, Novalis LifeSciences LLC, Omega Funds, PMV, Yijing Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does eTheRNA Immunotherapies do?
- Etherna is an RNA-LNP technology company that develops proprietary RNA chemistry and lipid nanoparticle delivery platforms for nucleic acid–based therapeutics, and partners with pharma and biotech organizations from early discovery through clinical development. It also runs its own therapeutic pipeline and operates a cGMP-accredited RNA manufacturing facility in Niel, Belgium.
- Who are eTheRNA Immunotherapies's investors?
- eTheRNA Immunotherapies's investors include Fund+, PMV, Boehringer Ingelheim Venture Fund, EQT Life Sciences, Novalis LifeSciences, Omega Funds, PWV.
- Where is eTheRNA Immunotherapies headquartered?
- eTheRNA Immunotherapies is headquartered in Niel, BE.